A biomarker is a biological feature that can be measured in tissue, blood, or other body fluids. In cancer care, biomarker testing may look for genes, proteins, or other molecules that can help doctors identify a cancer, estimate how it may behave, or select treatment options.
A tumor marker is a type of biomarker that may be found in blood, tissue, bone marrow, or other body fluids and can sometimes be linked to cancer. However, tumor markers are not always specific to cancer, and some can also be elevated in noncancerous conditions. That is why doctors usually interpret them together with imaging, pathology, symptoms, and other clinical findings.
Biomarker and tumor marker testing can support care in several ways. Depending on the cancer type, they may help confirm a diagnosis, guide treatment choices, monitor how well therapy is working, or help watch for signs that the disease has returned. Not every marker is useful for every cancer, and not every patient will need the same tests.
This is one reason cancer care has become more individualized. Instead of relying only on where the cancer started in the body, doctors may also look at the tumor’s molecular profile to decide whether a targeted therapy, immunotherapy, or another approach is more appropriate.
Some biomarkers help doctors match patients to treatments that are more likely to work for their specific cancer. NCI notes that biomarker testing can identify changes in a cancer that may help guide treatment choices.
In some situations, changes in marker levels over time may help show whether treatment appears to be working, although results must be interpreted carefully and in context.
Certain markers may help doctors watch for signs that a cancer has returned or changed after treatment, especially when used alongside scans and clinical review.
Because cancers can behave differently from one person to another, biomarker information can help shape a more tailored care plan over time.
It is natural to assume that a “high” marker automatically means cancer is worsening, but that is not always true. Some tumor markers are not specific, some cancers do not produce useful markers at all, and results can be influenced by other medical factors. This is why doctors usually avoid making major decisions based on a single test result alone.
Patients may also hear about repeat biomarker testing during treatment or after a cancer changes. This can happen because cancers may evolve over time, and updated molecular information can sometimes reveal new treatment opportunities or explain why a therapy is no longer working as expected.
The effectiveness of cancer treatment varies among each patient.
A liquid biopsy is a laboratory test performed on blood, urine, or another body fluid to look for cancer cells or small pieces of DNA, RNA, or other molecules released by tumors. Because it can be repeated over time, liquid biopsy may help doctors monitor molecular changes in a less invasive way than repeated tissue biopsies in some settings.
This can be especially useful when doctors want to track how a cancer is changing, look for possible resistance-related changes, or identify biomarkers that may guide treatment. At the same time, liquid biopsy does not replace every tissue biopsy, and its usefulness depends on the cancer type and clinical situation.
If your care team recommends biomarker or tumor marker testing, it usually means they want more detailed information to guide the next step. That may involve tissue from a biopsy, a blood test, or another type of sample depending on the purpose of testing. Questions patients often ask include:
What is this test looking for?
How will the result affect treatment decisions?
Is this test for diagnosis, monitoring, or both?
Will I need this test repeated later?
These are reasonable questions, because the value of testing depends on how the results will be used in the context of the overall care plan.
Biomarkers, tumor markers, and liquid biopsy are helping move cancer care toward a more precise and personalized model. They do not replace imaging, pathology, or clinical judgment, but they can add important insight into what the cancer is doing and how treatment may be tailored. As research continues, these tools are likely to play an even bigger role in helping doctors make more informed decisions and helping patients better understand their care.
National Cancer Institute. Biomarker Testing for Cancer Treatment.
https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment
National Cancer Institute. Definition of biomarker testing.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker-testing
National Cancer Institute. Definition of biomarker.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
National Cancer Institute. Tumor Markers.
https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet
National Cancer Institute. Definition of tumor marker.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-marker
National Cancer Institute. Definition of tumor marker test.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-marker-test
National Cancer Institute. Definition of liquid biopsy.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy
National Cancer Institute. Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care.
https://www.cancer.gov/news-events/cancer-currents-blog/2017/liquid-biopsy-detects-treats-cancer
National Cancer Institute. Tumor Marker Tests in Common Use.
https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list
Precision medicine provides patients with clearer and more personalized treatment guidelines
Learn how precision medicine can help with your cancer treatment
The effectiveness of cancer treatment varies among each patient.